Head of legal, ethics, compliance and quality | Novo Nordisk
Damla Aygün Yararcan
Head of legal, ethics, compliance and quality | Novo Nordisk
Team size: Four
What strategic priorities are guiding you and your team in 2024?
In 2024, our team is guided by strategic priorities that reflect the recent reorganisation within our newly established NERM Cluster. One of our key strategic priorities involves the recent transition of the quality function from the medical and regulatory department to legal, ethics and compliance department. My focus is to ensure a smooth transition and to find effective ways for both legal and quality colleagues to collaborate. This transition presents an opportunity for us to align our efforts and work closely with quality colleagues to seamlessly integrate quality processes within the new framework.
Additionally, we are dedicated to continuously identifying best practices across the NERM Cluster affiliates and unifying them to create a cohesive approach. Our aim is to share and implement these best practices across all affiliates, fostering a culture of collaboration and knowledge sharing within the cluster.
As we adapt our working style, we are committed to upholding business ethics and maintaining quality standards. We will continue to drive the legal and compliance agenda across the cluster, providing pragmatic, bold, and compliant business solutions to address the unique challenges of our diverse markets.
These strategic priorities underscore our commitment to adapting to organizational changes, fostering collaboration, and driving unified practices across our newly established NERM Cluster.
Do you have a cause, business-related or otherwise, that you are passionate about?
As an in-house counsel and management team member in a pharmaceutical sector, my primary focus lies in ensuring the optimal delivery of care to the patients who depend on our products. Most of our offerings are considered lifesaving, underscoring the importance of collaborating closely with healthcare authorities and professionals to ensure patients have access to essential treatments. Placing patients at the core of our operations significantly impacts the way we approach our work, emphasising their well-being in every aspect of our endeavors.
Head of Legal, Business Area Middle East, Africa, CIS (BAMEAC) | Novo Nordisk